Compounds and compositions as protein kinase inhibitors
View Patent ↗The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
1. A compound having Formula (1):
or pharmaceutically acceptable salts thereof; wherein
W is
A 1 and A 4 are independently C;
each A 2 and A 3 is C;
R 1 and R 2 together form an optionally substituted 5-6 membered aryl, or heteroaryl or heterocyclic ring comprising 1-3 nitrogen atoms;
R 3 is (CR 2 ) 0-2 SO 2 R 12 , (CR 2 ) 0-2 SO 2 NRR 12 , (CR 2 ) 0-2 C(O)O 0-1 R 12 , (CR 2 ) 0-2 CONRR 12 , CO 2 NH 2 , or cyano;
R 4 , R 7 and R 10 are independently H;
R, R 5 and R 5′ are independently H or C 1-6 alkyl;
R 6 is halo or O(C 1-6 alkyl);
R 8 and R 9 are independently C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo or X, or one of R 8 and R 9 is H; and provided one of R 8 and R 9 is X;
X is (CR 2 ) q Y, cyano, C(O)O 0-1 R 12 , CONR(R 12 ), CONR(CR 2 ) p NR(R 12 ), CONR(CR 2 ) p OR 12 , CONR(CR 2 ) p SR 12 , CONR(CR 2 ) p S(O) 1-2 R 12 or (CR 2 ) 1-6 NR(CR 2 ) p OR 12 ;
Y is an optionally substituted 3-12 membered carbocyclic ring, a 5-12 membered aryl, or a 5-12 membered heteroaryl or heterocyclic ring comprising N, O and/or S and attached to A 2 or A 3 or both via a carbon atom of said heteroaryl or heterocyclic ring when q in (CR 2 ) q Y is 0;
R 12 is an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R 12 is H, C 1-6 alkyl; and
n is 0; and
p and q are independently 0-4.
2. The compound of claim 1 , wherein R 3 is SO 2 R 12 , SO 2 NH 2 , SO 2 NRR 12 , CO 2 NH 2 , CONRR 12 , C(O)O 0-1 R 12 , or cyano; and
R 12 is C 1-6 alkyl, an optionally substituted C 3-7 cycloalkyl, C 3-7 cycloalkenyl, pyrrolidinyl, piperazinyl, piperidinyl or morpholinyl.
3. The compound of claim 1 , wherein said compound is selected from the group consisting of
or pharmaceutically acceptable salts thereof.
4. The compound of claim 1 , wherein said compound is selected from the group consisting of:
or pharmaceutically acceptable salts thereof.
5. The compound of claim 1 , wherein said compound is selected from the group consisting of
or pharmaceutically acceptable salts thereof.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 3 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 4 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 5 and a pharmaceutically acceptable carrier.
10. The compound of claim 1 , wherein said compound is N6-(4-(1-ethylpiperidin-4-yl)-2-isopropoxy-5-methylphenyl)-N4-(2-(isopropylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, or pharmaceutically acceptable salts thereof.
11. The compound of claim 1 , wherein said compound is N6-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine, or pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier.